Niagen Bioscience Inc (NAGE) Stock Price, Quote & News

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, in...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 388 6706

Website: www.niagenbioscience.com

Address:

10900 Wilshire Blvd, Suite 600, Los Angeles, United States

bochico Aug. 19 at 2:08 PM

$NAGE nice little move up. more to come?

0 · Reply

wycliff Aug. 18 at 4:45 PM

$NAGE https://lnkd.in/p/e9XUgKu9

0 · Reply

okeydokey_artichokey Aug. 18 at 2:31 PM

$NAGE Folks here may want to look into rcel. Still early days with a great product and solids clinical results. Not a drug company. glta

0 · Reply

SnowyDingo Aug. 17 at 7:53 PM

$NAGE $NSRGY $LRLCY $HIMS . Rumor is that $COST deal underway

0 · Reply

wycliff Aug. 17 at 7:10 PM

$NAGE https://lnkd.in/p/eW-VCuZR

0 · Reply

wycliff Aug. 17 at 7:07 PM

$NAGE https://x.com/drmikehart/status/2089427452246306985/video/1?s=42

0 · Reply

Impalas283 Aug. 17 at 12:34 PM

$NAGE I did not know this before yesterday, but in June of this year they were hit with a class action law suit for false advertising. No one here has talked about this that I have seen. That, along with home injections, (bad idea) should do wonders for this stock.

0 · Reply

wycliff Aug. 16 at 4:00 AM

$NAGE https://finance.yahoo.com/community/post/d265ad47-1269-4e38-bbae-97ea3f0c32cc

0 · Reply

MattManzanita Aug. 15 at 5:49 PM

$NAGE Rob Fried mentioned recently that they have not yet determined what to ultimately use in a skincare product. I thought the options were between NR and NRH. He mentioned too that the product would not be in pillow form, as was used in the recent experimental test product that sold out. Could it be this? "Nicotinamide riboside trioleate chloride (NRTOCl) is a specialized oil-soluble, hydrophobic derivative of nicotinamide riboside (NR). Created to improve chemical stability in water and emulsions, it allows vitamin B3-based NAD+ precursors to be added to ready-to-drink beverages and moist foods where standard nicotinamide riboside chloride (NRCl) normally degrades. 1, 2, 3

1 · Reply

SnowyDingo Aug. 15 at 5:43 PM

$NAGE CEO spent the earnings call seeding a takeout narrative. 4 buyer universes: 🛒 CPG (Thorne/PG $3.8B comp) → $NSRGY (Nestlé Health Science) 💄 Beauty ("2 global skincare cos") → $LRLCY (L'Oréal) 💊 Pharma (Reata/ $7.3B comp) → $BIIB, for NB4168 📱 Telehealth → $HIMS But: comp gated on $15 PSUs, so he's incentivized to talk his book. "In discussions" ≠ deal. No name, no LOI, no timeline. Real tell = a signed exclusive skincare supply deal w/ a named $LRLCY-tier buyer. Until then it's CEO optionality, not a catalyst

1 · Reply

Meet Niagen Bioscience: Fly exclusive interview with CFO Ozan Pamir

Aug 12, 2026, 8:32 AM EDT - 7 days ago

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Aug 11, 2026, 2:00 PM EDT - 7 days ago

Niagen Bioscience Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-06T18:05:56.000Z - 12 days ago

Niagen Bioscience CFO highlights telehealth as ‘high-expectation growth channel’

2026-08-06T14:05:45.000Z - 13 days ago

Bananas, Bread, Bones…Walmart Seals Healthy Aging Deal With Niagen Bioscience

WMT

2026-08-06T12:42:23.000Z - 13 days ago

Niagen Bioscience announces Tru Niagen is now available at Walmart

WMT

Aug 6, 2026, 8:34 AM EDT - 13 days ago

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

2026-08-05T11:50:28.000Z - 14 days ago

Niagen Bioscience price target lowered to $10 from $12 at Roth Capital

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Niagen Bioscience Earnings Call Transcript: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Niagen Bioscience Earnings release: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Niagen Bioscience Quarterly report: Q2 2026

Aug 4, 2026, 4:30 PM EDT - 14 days ago

Niagen Bioscience Slides: Q2 2026

2026-08-04T20:13:22.000Z - 14 days ago

Niagen Bioscience sees ecommerce business growing 10%-15% in FY26

2026-08-04T20:05:37.000Z - 14 days ago

Niagen Bioscience reports Q2 EPS 1c vs 4c last year

Aug 4, 2026, 4:02 PM EDT - 14 days ago

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

2026-08-03T12:46:16.000Z - 16 days ago

Niagen Bioscience selects Evotec to advance development for NB4168

EVO

Aug 3, 2026, 8:32 AM EDT - 16 days ago

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

EVO

2026-07-28T12:41:24.000Z - 22 days ago

Niagen Bioscience announces publication on muscle epigenetic age

Jul 28, 2026, 8:32 AM EDT - 22 days ago

Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging

Jul 27, 2026, 8:32 AM EDT - 23 days ago

Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference

Jul 21, 2026, 8:32 AM EDT - 4 weeks ago

Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

2026-07-21T12:00:36.000Z - 4 weeks ago

Niagen Bioscience price target lowered to $11 from $12 at Ladenburg

2026-07-16T12:46:33.000Z - 4 weeks ago

Niagen Bioscience appoints Kale as Senior Director of Global External Research

Jul 16, 2026, 8:32 AM EDT - 4 weeks ago

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

Jul 15, 2026, 11:00 AM EDT - 4 weeks ago

Niagen Bioscience Transcript: Fireside chat

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

Niagen Bioscience Slides: Corporate presentation

2026-07-13T12:35:07.000Z - 5 weeks ago

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Jul 13, 2026, 8:32 AM EDT - 5 weeks ago

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Jul 9, 2026, 8:32 AM EDT - 5 weeks ago

Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026

2026-07-08T12:40:25.000Z - 6 weeks ago

Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Jul 8, 2026, 8:32 AM EDT - 6 weeks ago

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

2026-07-06T19:10:21.000Z - 6 weeks ago

Niagen Bioscience initiated with a Buy at Freedom Broker

Jun 29, 2026, 8:00 AM EDT - 7 weeks ago

Niagen Bioscience Registration statement: Registration filing

2026-06-29T10:25:42.000Z - 7 weeks ago

Niagen Bioscience files $125M mixed securities shelf

Jun 11, 2026, 2:40 PM EDT - 2 months ago

Niagen Bioscience Transcript: 16th Annual East Coast IDEAS Conference

Jun 3, 2026, 8:34 AM EDT - 2 months ago

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

2026-06-02T15:25:33.000Z - 2 months ago

Niagen Bioscience renames CERP to Niagen Research Program

Jun 2, 2026, 8:32 AM EDT - 2 months ago

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

2026-05-11T10:46:50.000Z - 3 months ago

Niagen Bioscience price target lowered to $11 from $12 at H.C. Wainwright

May 8, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

2026-05-07T20:07:38.000Z - 3 months ago

Niagen Bioscience price target lowered to $12 from $13 at Roth Capital

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Niagen Bioscience Slides: Q1 2026

May 6, 2026, 4:02 PM EDT - 3 months ago

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

May 6, 2026, 7:00 AM EDT - 3 months ago

Niagen Bioscience Slides: Corporate presentation

May 4, 2026, 8:32 AM EDT - 3 months ago

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Niagen Bioscience Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Niagen Bioscience Proxy statement: Proxy filing

Apr 28, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™

Apr 22, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Apr 9, 2026, 8:32 AM EDT - 4 months ago

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

Mar 31, 2026, 8:34 AM EDT - 5 months ago

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

OSW

Mar 19, 2026, 8:32 AM EDT - 5 months ago

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Mar 18, 2026, 8:32 AM EDT - 5 months ago

Niagen Bioscience to Present at the 38th Annual ROTH Conference

Mar 17, 2026, 8:32 AM EDT - 5 months ago

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

Mar 10, 2026, 8:32 AM EDT - 5 months ago

Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Niagen Bioscience Slides: Q4 2025

Mar 4, 2026, 4:02 PM EST - 5 months ago

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

Mar 4, 2026, 7:00 AM EST - 6 months ago

Niagen Bioscience Slides: Corporate presentation

Feb 26, 2026, 7:02 AM EST - 6 months ago

Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Feb 25, 2026, 8:32 AM EST - 6 months ago

Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen®

Feb 9, 2026, 8:34 AM EST - 6 months ago

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

Feb 6, 2026, 8:32 AM EST - 6 months ago

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

Jan 15, 2026, 11:30 AM EST - 7 months ago

Niagen Bioscience Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 8:34 AM EST - 7 months ago

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

Dec 22, 2025, 8:32 AM EST - 8 months ago

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Nov 13, 2025, 8:32 AM EST - 9 months ago

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Nov 12, 2025, 7:52 PM EST - 9 months ago

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Nov 6, 2025, 8:07 AM EST - 10 months ago

Niagen Bioscience Announces $10 Million Share Repurchase Program

Nov 4, 2025, 4:30 PM EST - 10 months ago

Niagen Bioscience Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Niagen Bioscience Earnings release: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Niagen Bioscience Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 10 months ago

Niagen Bioscience Slides: Q3 2025

Nov 4, 2025, 4:02 PM EST - 10 months ago

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Nov 4, 2025, 7:00 AM EST - 10 months ago

Niagen Bioscience Slides: Investor presentation

Oct 21, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 6, 2025, 8:32 AM EDT - 11 months ago

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Oct 1, 2025, 8:32 AM EDT - 11 months ago

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Sep 16, 2025, 8:32 AM EDT - 1 year ago

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Aug 12, 2025, 12:00 PM EDT - 1 year ago

Niagen Bioscience Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q2 2025

Aug 6, 2025, 4:02 PM EDT - 1 year ago

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Aug 4, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Jul 23, 2025, 8:34 AM EDT - 1 year ago

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 14, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Jul 8, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Jun 20, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Jun 11, 2025, 8:31 AM EDT - 1 year ago

Niagen Bioscience to Participate in the BIO 2025 International Convention

Jun 9, 2025, 2:15 PM EDT - 1 year ago

Niagen Bioscience Transcript: 25th Annual Consumer Growth and E-Commerce Conference

Jun 9, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Jun 4, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

May 9, 2025, 7:00 AM EDT - 1 year ago

Niagen Bioscience Slides: Corporate Presentation

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Niagen Bioscience Slides: Q1 2025

May 7, 2025, 4:02 PM EDT - 1 year ago

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 5, 2025, 8:32 AM EDT - 1 year ago

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

bochico Aug. 19 at 2:08 PM

$NAGE nice little move up. more to come?

0 · Reply

wycliff Aug. 18 at 4:45 PM

$NAGE https://lnkd.in/p/e9XUgKu9

0 · Reply

okeydokey_artichokey Aug. 18 at 2:31 PM

$NAGE Folks here may want to look into rcel. Still early days with a great product and solids clinical results. Not a drug company. glta

0 · Reply

SnowyDingo Aug. 17 at 7:53 PM

$NAGE $NSRGY $LRLCY $HIMS . Rumor is that $COST deal underway

0 · Reply

wycliff Aug. 17 at 7:10 PM

$NAGE https://lnkd.in/p/eW-VCuZR

0 · Reply

wycliff Aug. 17 at 7:07 PM

$NAGE https://x.com/drmikehart/status/2089427452246306985/video/1?s=42

0 · Reply

Impalas283 Aug. 17 at 12:34 PM

0 · Reply

wycliff Aug. 16 at 4:00 AM

$NAGE https://finance.yahoo.com/community/post/d265ad47-1269-4e38-bbae-97ea3f0c32cc

0 · Reply

MattManzanita Aug. 15 at 5:49 PM

1 · Reply

SnowyDingo Aug. 15 at 5:43 PM

1 · Reply

MattManzanita Aug. 14 at 11:03 PM

$NAGE Age-Dependent Progression of Neurological Involvement in PRPP Deficiency: Insights from a Four-Generation Family and Systematic Review by Bartosz Rodziewicz 1,*ORCID,Mikołaj Kacperski 1ORCID,Kacper Kisiński 1,Marta Zawadzka 1,*ORCID,Anna Kalicka 2,Agnieszka Sawicka 1,Beata Lipska-Ziętkiewicz 2,3 and

0 · Reply

wycliff Aug. 14 at 10:52 PM

$NAGE https://lnkd.in/p/e6CmiDFf

0 · Reply

wycliff Aug. 14 at 10:03 PM

$NAGE https://lnkd.in/p/eFwRZxD9

0 · Reply

cynicaloptimist Aug. 14 at 5:10 PM

$NAGE Worst stock in entire portfolio. This got away from me, misplaced conviction. Live and learn to trade another day.

1 · Reply

tymtested Aug. 14 at 11:20 AM

$NAGE buy buy NAGE!

0 · Reply

wycliff Aug. 13 at 5:59 PM

$NAGE https://www.reddit.com/r/NicotinamideRiboside/s/sGnv9y2syL

0 · Reply

wycliff Aug. 13 at 5:34 PM

$NAGE short interest on July 31 was reported at 4,545,665 down from July 15 where it came in at 4,786424

0 · Reply

Rainmaker64 Aug. 13 at 4:21 PM

$NAGE For years I heard Fried say that a skin cream was just not possible as NR was unstable in liquid. The skin cream (I think he said moisturizer) launch in April 2027 may mean they have solved this issue or they are using a different molecule. Something to ponder...

1 · Reply

Yingtrader7 Aug. 13 at 4:07 PM

$NAGE BYE BYE NAGE

0 · Reply

Impalas283 Aug. 13 at 2:14 PM

$NAGE Maybe instead of home injections and skin care, they should have invested in making NR themselves, or at least come up with another supplier. That would have taken the risk of a single supplier off the table.

0 · Reply

wycliff Aug. 13 at 2:00 PM

$NAGE next year’s skin cream product may be a huge success

0 · Reply

wycliff Aug. 13 at 12:09 AM

$NAGE https://lnkd.in/p/eAcgs7Tc

0 · Reply

Market Cap	242.12M
Revenue (ttm)	129.42M
Net Income (ttm)	17.38M
EPS (ttm)	N/A
PE Ratio	18.88
Forward PE	23.23
Profit Margin	13.43%
Debt to Equity Ratio	0.00

Volume	518,600
Avg Vol	715,266
Day's Range	N/A - N/A
Shares Out	79.64M
Stochastic %K	67%
Beta	2.09
Analysts	Strong Sell
Price Target	$10.10